A Randomized Double-Blind Placebo Controlled Trial to Determine the Status of Post Knee Chondroplasty Patients Administered Theramine Versus Placebo in Addition to Post Surgery Analgesics

Sponsor
Targeted Medical Pharma (Industry)
Overall Status
Terminated
CT.gov ID
NCT01534286
Collaborator
(none)
8
1
2
16
0.5

Study Details

Study Description

Brief Summary

The purpose of this study will be to show the patient response to analgesics taken post surgery when taken in combination with Theramine as opposed to Theramine-like placebo. The data collected will be used to show that patients have a shorter and lower post operative pain measurement and the time to discontinuation of analgesics is less in the active comparator group.

Condition or Disease Intervention/Treatment Phase
Phase 4

Detailed Description

No other decription

Study Design

Study Type:
Interventional
Actual Enrollment :
8 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
A Randomized Double-Blind Placebo Controlled Trial to Determine the Status of Post Knee Chondroplasty Patients Administered Theramine Versus Placebo in Addition to Post Surgery Analgesics
Study Start Date :
Aug 1, 2012
Actual Primary Completion Date :
Dec 1, 2013
Actual Study Completion Date :
Dec 1, 2013

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: Theramine

Theramine 2 capsules three times per day in addition to post surgical analgesic medication.

Drug: Theramine
Theramine 2 capsules 3 times per day

Placebo Comparator: Theramine-like Placebo

Theramine-like placebo 2 capsules three times per day in addition to post surgical analgesic medication.

Drug: Theramine- like placebo
Theramine-like placebo capsules 2 three times daily

Outcome Measures

Primary Outcome Measures

  1. Dose reduction of analgesic. [28 days]

    The primary efficacy outcome will be the overall dose reduction of analgesic in the Theramine active group versus the Theramine placebo group.

Secondary Outcome Measures

  1. Change in Visual Analogue Scale Evaluation (VASE) [28 days]

  2. Change in second Knee pain scale. [28 Days]

  3. Time to discontinuation of analgesic. [28 days]

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 65 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Diagnosed knee pain requiring chondroplasty knee arthroscopic surgery.

  • Men and non-pregnant, non-lactating women over the age of 18 and under the age of 75, able to read, understand and sign English-language informed consent.

  • If using psychoactive medication which might have analgesic effects, (i.e. anti-depressants or anti-consultants), treatment must be stable for at least three (3) months prior to study.

  • For men and women of child-bearing potential, must be willing to use adequate contraception and not be pregnant or impregnate their partner during the entire time of study.

  • Must be willing to commit to all clinical visits during study-related procedures.

  • Require use of narcotics for pain relief.

Exclusion Criteria:
  • Patients with significant neurologic impairment, as diagnosed on screening physical examination.

  • Patients not fluent in English.

  • Patients currently involved in a Workman's Compensation case related to this procedure.

  • Receipt of an oral intramuscular or soft-tissue injection of corticosteroid within one (1) month prior to screening.

  • History of substance abuse.

  • History of malignancy, other than basal or squamous cell of the skin within the last 5 years.

  • Tibial plateau fracture within 6 months prior to surgery.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Andrews-Paulos Research & Education Institute Gulf Breeze Florida United States 32561

Sponsors and Collaborators

  • Targeted Medical Pharma

Investigators

  • Principal Investigator: Gregory V. Hickman, MD, Andrews-Paulos Research & Education Institute

Study Documents (Full-Text)

None provided.

More Information

Additional Information:

Publications

None provided.
Responsible Party:
Targeted Medical Pharma
ClinicalTrials.gov Identifier:
NCT01534286
Other Study ID Numbers:
  • 0201302
First Posted:
Feb 16, 2012
Last Update Posted:
May 5, 2016
Last Verified:
May 1, 2016
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Keywords provided by Targeted Medical Pharma

Study Results

No Results Posted as of May 5, 2016